-

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

– Toward Health Equity Oncology Grant Supports Initiatives to Break the Cycle of Health Inequity –

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity (THE) Oncology Grant™. The funding will support evidence-based interventions that address barriers to care and social determinants of health including patient navigator training, cultural competency training, and services combating barriers such as transportation.

“Gilead is committed to advancing health equity and supporting these vital patient advocacy organizations working to close gaps in breast cancer care,” said Deborah H. Telman, Executive Vice President, Corporate Affairs and General Counsel, Gilead Sciences. “We believe our Toward Health Equity Oncology Grant awards contribute important new understanding to advance and care for anyone living with breast cancer. We look forward to seeing their dynamic, innovative programs come to life.”

Breast cancer affects more American women than any other type of cancer, besides skin cancer.1 But due to social, environmental, and economic disparities, people of color are at increased risk of developing or dying from breast cancer.2 In 2023, an estimated 300,000 women will be diagnosed with breast cancer in the U.S. and more than 43,000 women will die from breast cancer.3

The 2023 funding will support evidence-based interventions that focus on patient navigation and digital/mobile interventions to improve health equity. All 2023 grantees were chosen based on several criteria including their ability to create measurable and sustainable change toward health equity.

THE Oncology Grant builds on Gilead’s 2022 program, which provided $5.7 million in grants to 21 U.S. organizations for programs working to advance health equity for Black people impacted by triple-negative breast cancer. The new grantees serve historically neglected and underrepresented communities including Hispanic, Jewish, LGBTQIA, Indigenous American, and others, and will work to address access disparities in the treatment of breast cancer.

The 2023 THE Oncology Grant awardees include:

  • Asociación Latina De Asistencia Y Prevención Del Cáncer De Mama
  • Association of Community Cancer Centers
  • Coalition of Blacks Against Breast Cancer
  • Family Reach Foundation
  • Franklin Square Hospital Center, Inc.
  • George Washington University
  • Harris County Hospital District Foundation
  • Mary Bird Perkins Cancer Center
  • New Orleans Musicians Assistance Foundation
  • Nueva Vida Inc.
  • Patient Advocate Foundation Inc.
  • Shanti Project Inc.
  • Share Self-Help For Women With Breast Or Ovarian Cancer, Inc.
  • Sharsheret Inc.
  • Sisters Working It Out NFP
  • St. Vincent Hospital
  • Susan G Komen Breast Cancer Foundation
  • The Ellie Fund
  • UC Davis, Comprehensive Cancer Center, Center for Advancing Cancer Health Equity
  • Vietnamese American Cancer Foundation
  • Virtua Health Foundation, Inc.
  • Women’s Cancer Care and Research Program (WeCARE) at UC Davis
  • Women’s Cancer Resource Center
  • Young Survival Coalition, Inc.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, inflammation and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead’s medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative® to community organizations that are working to combat HIV in the U.S. South. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

1 Breast Cancer Statistics. The American Society of Clinical Oncology. Breast Cancer: Statistics | Cancer.Net. Last accessed January 31, 2023.
2 Cancer Disparities. The National Cancer Institute. Cancer Disparities - NCI. Last accessed January 31, 2023.
3 Key Statistics for Breast Cancer. The American Cancer Society. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html, last accessed January 31, 2023.

Contacts

Hayley Home, Media
public_affairs@gilead.com
Meaghan Smith, Media
public_affairs@gilead.com

Gilead Sciences, Inc.

NASDAQ:GILD

Release Summary
Gilead awards $7.6 million in grants to 24 U.S.-based organizations through the newly created Toward Health Equity Oncology Grant(TM).
Release Versions

Contacts

Hayley Home, Media
public_affairs@gilead.com
Meaghan Smith, Media
public_affairs@gilead.com

More News From Gilead Sciences, Inc.

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Both KITE-753 and...

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These new...

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina, N...
Back to Newsroom